Clinical Psychiatry News Digital Network In addition, levomilnacipran SR is greater than 10-fold more selective for norepinephrine reuptake inhibition than either duloxetine or venlafaxine. The drug is currently under review at the Food and Drug Administration for possible marketing approval ...
PR Newswire (press release) The loss of patent exclusivity of other key brands such as Cymbalta ( duloxetine ), OxyContin (oxycodone) and Lidoderm (lidocaine) scheduled in the year 2013 will have a profound impact on the growth of the overall market. North America was the largest ... and more »
